- Home
- IGR vs ZYME Comparison
IGR vs ZYME Comparison
Compare IGR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- ZYME
- Stock Information
- Founded
- IGR 2004
- ZYME 2003
- Country
- IGR United States
- ZYME United States
- Employees
- IGR N/A
- ZYME N/A
- Industry
- IGR Finance Companies
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- ZYME Health Care
- Exchange
- IGR Nasdaq
- ZYME Nasdaq
- Market Cap
- IGR 770.8M
- ZYME 751.6M
- IPO Year
- IGR N/A
- ZYME 2017
- Fundamental
- Price
- IGR $4.95
- ZYME $14.14
- Analyst Decision
- IGR
- ZYME Buy
- Analyst Count
- IGR 0
- ZYME 6
- Target Price
- IGR N/A
- ZYME $19.17
- AVG Volume (30 Days)
- IGR 747.7K
- ZYME 505.4K
- Earning Date
- IGR 01-01-0001
- ZYME 10-31-2024
- Dividend Yield
- IGR 13.93%
- ZYME N/A
- EPS Growth
- IGR N/A
- ZYME N/A
- EPS
- IGR N/A
- ZYME N/A
- Revenue
- IGR N/A
- ZYME $62,199,000.00
- Revenue This Year
- IGR N/A
- ZYME $21.53
- Revenue Next Year
- IGR N/A
- ZYME N/A
- P/E Ratio
- IGR N/A
- ZYME N/A
- Revenue Growth
- IGR N/A
- ZYME N/A
- 52 Week Low
- IGR $3.88
- ZYME $7.97
- 52 Week High
- IGR $5.70
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- IGR 24.60
- ZYME 52.72
- Support Level
- IGR $4.87
- ZYME $12.48
- Resistance Level
- IGR $5.89
- ZYME $14.10
- Average True Range (ATR)
- IGR 0.12
- ZYME 0.72
- MACD
- IGR -0.07
- ZYME 0.02
- Stochastic Oscillator
- IGR 8.52
- ZYME 81.43
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is the United States based diversified, closed-end management investment company. Its objective is high current income and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities located mainly in the developed markets of North America, Europe, Australia, and Asia. Its portfolio of investments consists of different sectors such as diversified, retail, industrial, residential, hotels, healthcare, and other sectors.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.